belimumab   

GtoPdb Ligand ID: 6887

Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B
belimumab is an approved drug (FDA (2011), EMA (2011))
Compound class: Antibody
Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,4] , an immunostimulant essential for normal B cell maintenance and humoral immunity [5], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belimumab

References
1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Arthritis Rheum., 48 (11): 3253-65. [PMID:14613291]
2. Dörner T. (2006)
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
J Rheumatol Suppl, 77: 3-11. [PMID:16652439]
3. Lutalo PM, D'Cruz DP. (2014)
Update on belimumab for the management of systemic lupus erythematosus.
Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323]
4. Sabahi R, Anolik JH. (2006)
B-cell-targeted therapy for systemic lupus erythematosus.
Drugs, 66 (15): 1933-48. [PMID:17100405]
5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H et al.. (1999)
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.
J. Exp. Med., 189 (11): 1747-56. [PMID:10359578]